# US 2025/0017923 A1 · Pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0017923 A1
- Document ID: US20250017923A1
- Status: Published application
- Kind: A1
- Application number: 18/903,119
- Filed: 2024-10-01
- Published: 2025-01-16
- Earliest claimed: 2010-09-16
- Assignees: ViiV Healthcare Company
- Applicants: Viiv Healthcare Company
- Inventors: Deepak B. MUNDHRA; Rennan PAN
- Web page: https://patentgrep.com/patent/US20250017923A1

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present Invention relates to pharmaceutical compositions of (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.

## Claims

### Claim 1

A parenteral pharmaceutical suspension comprising 0.1-50% by weight a compound of formula (I)
0.1-10% by weight polysorbate,
0.1-10% by weight polyethylene glycol 3350, 4000 or 8000,
mannitol, and
water, and
wherein the suspension has mean particle size of 0.1-1 μm.

### Claim 2 (depends on 1)

The pharmaceutical suspension according to claim 1 for intramuscular administration.

### Claim 3 (depends on 2)

The pharmaceutical suspension according to claim 2 for once per month administration.

### Claim 4 (depends on 2)

The pharmaceutical suspension according to claim 2 for administration once every two months.

### Claim 5 (depends on 1)

The pharmaceutical suspension according to claim 1, wherein the suspension has a mean particle size of 0.1-0.5 μm.

### Claim 6 (depends on 2)

The pharmaceutical suspension according to claim 2, wherein the suspension has a mean particle size of 0.1-0.5 μm.

### Claim 7 (depends on 3)

The pharmaceutical suspension according to claim 3, wherein the suspension has a mean particle size of 0.1-0.5 μm.

### Claim 8 (depends on 4)

The pharmaceutical suspension according to claim 4, wherein the suspension has a mean particle size of 0.1-0.5 μm.

### Claim 9 (depends on 1)

The pharmaceutical suspension according to claim 1, wherein the suspension has been sterilized.

### Claim 10 (depends on 3)

The pharmaceutical suspension according to claim 3, wherein the suspension has been sterilized.

### Claim 11 (depends on 4)

The pharmaceutical suspension according to claim 4, wherein the suspension has been sterilized.

### Claim 12 (depends on 5)

The pharmaceutical suspension according to claim 5, wherein the suspension has been sterilized.

### Claim 13 (depends on 6)

The pharmaceutical suspension according to claim 6, wherein the suspension has been sterilized.

### Claim 14 (depends on 7)

The pharmaceutical suspension according to claim 7, wherein the suspension has been sterilized.

### Claim 15 (depends on 8)

The pharmaceutical suspension according to claim 8, wherein the suspension has been sterilized.

### Claim 16 (depends on 1)

The pharmaceutical suspension according to claim 1, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/mL PEG 3350.

### Claim 17 (depends on 2)

The pharmaceutical suspension according to claim 2, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/mL PEG 3350.

### Claim 18 (depends on 3)

The pharmaceutical suspension according to claim 3, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/mL PEG 3350.

### Claim 19 (depends on 4)

The pharmaceutical suspension according to claim 4, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/mL PEG 3350.

### Claim 20 (depends on 5)

The pharmaceutical suspension according to claim 5, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/mL polysorbate 20, and
20 mg/mL PEG 3350.

### Claim 21 (depends on 6)

The pharmaceutical suspension according to claim 6, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/mL polysorbate 20, and
20 mg/ml PEG 3350.

### Claim 22 (depends on 7)

The pharmaceutical suspension according to claim 7, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/ml PEG 3350.

### Claim 23 (depends on 8)

The pharmaceutical suspension according to claim 8, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/ml PEG 3350.

### Claim 24 (depends on 9)

The pharmaceutical suspension according to claim 9, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/mL polysorbate 20, and
20 mg/ml PEG 3350.

### Claim 25 (depends on 10)

The pharmaceutical suspension according to claim 10, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/ml PEG 3350.

### Claim 26 (depends on 11)

The pharmaceutical suspension according to claim 11, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/ml PEG 3350.

### Claim 27 (depends on 12)

The pharmaceutical suspension according to claim 12, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/mL PEG 3350.

### Claim 28 (depends on 13)

The pharmaceutical suspension according to claim 13, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/mL PEG 3350.

### Claim 29 (depends on 14)

The pharmaceutical suspension according to claim 14, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/mL PEG 3350.

### Claim 30 (depends on 15)

The pharmaceutical suspension according to claim 15, wherein the pharmaceutical suspension comprises
200 mg/ml compound of formula (I),
20 mg/ml polysorbate 20, and
20 mg/mL PEG 3350.
